- KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Byrd, J.C., Lucas, D.M., Mone, A.P., Kitner, J.B., Drabick, J.J., Grever, M.R. Blood (2003)